Nine Months Post-Covid mRNA ‘Vaccine’ Rollout, Substantial Birth Rate Drops in 13 European Countries, England/Wales, Australia, and Taiwan


Robert W. Chandler, MD, completed extensive research to write the article below. Some of the highlights of this important piece include:

  • Nine months following the rollout of the Covid-19 mRNA “vaccines,” substantial birth rate drops were seen in 13 of 19 European countries, England and Wales (one entity based on how data is published), Australia, and Taiwan.
  • The decline in births in Switzerland was the largest in 150 years – more than during two World Wars, the Great Depression, and the advent of widely available birth control.
  • There was an 8.3% drop in the birth rate in Germany through three quarters of 2022.
  • England and Wales had a 12% birth rate drop through June 2022, which is when their government stopped publishing data related to this.
  • Taiwan reported an alarming birth rate drop, but its data are incomplete.
  • Australian birth rates fell 21% from October to November 2021, followed by a 63% decrease from November to December 2021.
  • On August 25, 2022, the Swiss Hagemann group published a statement regarding the decline of live births in Europe: “My analysis puts the monthly birth figures in relation to the average of the last three years. In advance it should be noted that every single examined European country shows a monthly decline in birth rates of up to more than 10% compared to the last three years. I can be shown that this very alarming signal cannot be explained by infections with Covid-19. However, one can establish a clear temporal correlation to Covid vaccinations incidence in the age group of men and women between 18 and 49 years. Therefore, in-depth statistical and medical analyses have to be demanded.” [https://www.initiative-corona.info/fileadmin/dokumente/Geburtenrueckgang-Europe-EN.pdf]

I. Background

Pfizer’s “Preclinical Studies, 2.4 Nonclincial Overview” revealed concentration of lipid nanoparticles containing experimental mRNA in ovaries of Wistar rats. The study was completed in 48 hours. Unfortunately, the tissue levels of lipid nanoparticle and mRNA were rising sharply at the time the animals were sacrificed, and the biodistribution time course of LNP and mRNA remains largely unknown.

There has been no evidence located to date in the Pfizer records that necropsy examinations with special staining of ovarian tissues for spike proteins under light and electron microscopy were performed, which is an important omission. Additional animal studies were indicated but were not performed. Deficiencies were reviewed previously.

Sasha Latypova in a January 1, 2023, review of Pfizer’s Pre-Clinical (Pfizer document 2.4) testing concluded:

“The cursory nature of the entire preclinical program for mRNA injections conducted by Pfizer can be briefly summarized as “we did not find any safety signals because we did not look for them”. The omissions of standard safety studies and glaring scientific dishonesty in the studies that were performed are so obvious that they cannot be attributed to the incompetence of the manufacturers and regulators. Rather, the questions of fraud and willful negligence should be raised.”

Additional omissions occurred in Pfizer’s clinical trials:

  1. Critically, the Phase 2/3 Clinical Trial (Polack, et al.) involving over 40,000 subjects did not include pregnant women, at least not by design. A small number of pregnant women were injected, but no follow-up reporting on these women was provided.
  2. A 12/22/2022 paper by Irrarang, et al. identified dose-related effects in the distribution of IgG profile in humans after the second and third doses of Pfizer’s SARS-CoV-2 mRNA drug (BNT162b2):

Nine Months Post-Covid mRNA ‘Vaccine’ Rollout, Substantial Birth Rate Drops in 13 European Countries, England/Wales, Australia, and Taiwan

Figure 1: Dose-Related Shift in IgG Immunoglobulins

Nine Months Post-Covid mRNA ‘Vaccine’ Rollout, Substantial Birth Rate Drops in 13 European Countries, England/Wales, Australia, and Taiwan

Nine Months Post-Covid mRNA ‘Vaccine’ Rollout, Substantial Birth Rate Drops in 13 European Countries, England/Wales, Australia, and Taiwan

Figure 2: Gain in IgG 4 As the Number of LNP/mRNA Doses Increase

Figure 2 is a plot of the rise in IgG4 with successive doses of BNT162b2 after Dose 2. The significance of this IgG shift is only beginning to be explored. What is certain is that alteration of the IgG profile was not anticipated and therefore not studied.

Jessica Rose discusses these findings in the context of pregnancy noting:

“IgG can be passed to the foetus via the placental barrier via endosomes “within syncytiotrophoblasts of the placenta, through a pH dependent mechanism involving FcRn receptors, with a possible role for other IgG Fc receptors, yet to be fully elucidated”. They also showed a preferential transfer of IgG4 (and IgG1 and IgG3). Right. So (sic) what is the effect, therefore, on the foetus when there is a dramatic shift in IgG subclass ratio to subclass IgG4? I cannot imagine that the effects would be nil.

Röltgen, et al. dispelled the notion that the LNP/mRNA products briefly remain at the injection site and in local lymph nodes when they identified mRNA in local lymph nodes for two months after injection, at which point the study ended. So, it is unknown how long mRNA persists, where it is located, what it does to the host genome, and for how long it produces a largely unidentified artificial protein(s).

Long-term data is limited at present but is accruing. The studies promised by Pfizer and the Centers for Disease Control and Prevention (CDC) have not appeared.

The control group that was meant to be followed for two years was unblinded after a few months, which contaminated the group. Eliminating the control group was tragic decision.

II. Recommendations During Pregnancy

Remarkably, in spite of concentration of both lipid nanoparticles and mRNA in the ovaries of experimental animals, dose-related effects in animals and humans, and no testing in pregnant women during clinical trials or surveillance following the Experimental Use Authorization (EUA) granted by the Food and Drug Administration (FDA) December 14, 2020, the Centers for Disease Control and Prevention (CDC) and the American College of Obstetrics and Gynecology (ACOG) have recommended use of LNP/mRNA products in pregnant women without knowledge of either the short-term or long-term effects of what is contained in the vials of LNP/mRNA and their effects on the human reproductive system.


Leave a Reply

Your email address will not be published. Required fields are marked *